Case Report

Three cases of glycogenic hepatopathy mimicking acute and relapsing hepatitis in type I diabetes mellitus

Jae Hwang Cha1, Sang Ho Ra1, Yu Mi Park1, Yong Kwan Ji1, Ji Hyun Lee1, So Yeon Park1, Soon Koo Baik1, Sang Ok Kwon1, Mee Yon Cho2, and Moon Young Kim1

1Department of Internal Medicine and 2Department of Pathology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea

INTRODUCTION

Glycogenic hepatopathy (GH) was first identified at 1930 and it is characterized by elevated liver enzyme, hepatomegaly, and glycogen accumulation within hepatocytes and it can be found in patients with type I Diabetes Mellitus (DM) with poorly controlled blood sugar.1,2 Clinically, GH has been known to have benign nature; however it is difficult to distinguish with nonalcoholic fatty liver disease (NAFLD) which could progress into advance liver disease without histological confirmation.2,3 Recently, we have diagnosed three cases of GH presented marked serum transaminases elevation more than 30 times of upper normal range as like acute hepatitis with poorly controlled type I DM history. Since the first report, about 15 cases suspected as GH have been described in adults over the world. In Korea, before this report, only 2 cases of GH have been reported for adults, however, one case showed only mild AST elevation (65 U/L) and normal range of ALT and the other case showed mild liver enzyme elevation during diabetic ketoacidosis (DKA) management.4,5 On the contrary, our three cases of GH in this report showed dramatic elevation of liver enzyme as like acute hepatitis with poorly controlled type I DM history. Since the first report, about 15 cases suspected as GH have been described in adults over the world. In Korea, before this report, only 2 cases of GH have been reported for adults, however, one case showed only mild AST elevation (65 U/L) and normal range of ALT and the other case showed mild liver enzyme elevation during diabetic ketoacidosis (DKA) management.4,5 On the contrary, our three cases of GH in this report showed dramatic elevation of liver enzyme as like acute hepatitis with sustained fluctuation as like relapsing hepatitis, and these findings are very rare and unique even among the all reports of GH over the world. So, we present these cases with literature review.

Keywords: Glycogen hepatopathy; Transaminase; Type I diabetes mellitus

Glycogenic hepatopathy (GH) is an uncommon cause of serum transaminase elevation in type I diabetes mellitus (DM). The clinical signs and symptoms of GH are nonspecific, and include abdominal discomfort, mild hepatomegaly, and transaminase elevation. In this report we describe three cases of patients presenting serum transaminase elevation and hepatomegaly with a history of poorly controlled type I DM. All of the cases showed sudden elevation of transaminase to more than 30 times the upper normal range (like in acute hepatitis) followed by sustained fluctuation (like in relapsing hepatitis). However, the patients did not show any symptom or sign of acute hepatitis. We therefore performed a liver biopsy to confirm the cause of liver enzyme elevation, which revealed GH. Clinicians should be aware of GH so as to prevent diagnostic delay and misdiagnosis, and have sufficient insight into GH; this will be aided by the present report of three cases along with a literature review. (Clin Mol Hepatol 2013;19:421-425)

Abbreviations:
ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AMA, Anti-Mitochondrial Antibodies; ANA, Anti-Nuclear Antibody; Anti-HCV, antibody to hepatitis C virus; ASMA, Anti-smooth muscle antibody; AST, aspartate aminotransferase; BMI, body mass index; DM, Diabetes Mellitus; GH, Glycogenic hepatopathy; HbA1c, hemoglobin A1c; HBsAg, hepatitis B surface antigen; HDL, high-density lipoprotein; H&E, hematoxylin and eosin; NAFLD, Non-alcoholic fatty liver disease; PAS, periodic acid-Schiff; TB, Total bilirubin; TG, triglyceride

Corresponding author: Moon Young Kim
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Wonju Christian Hospital, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju 220-701, Korea
Tel. +82-33-741-1225, Fax. +82-33-741-1228
E-mail: drkimmy@yonsei.ac.kr

Received: Oct. 4, 2012 / Revised: Oct. 10, 2012 / Accepted: Oct. 17, 2012
CASE REPORT

Case 1

A 22-year old female was referred to a hepatologist for evaluation of elevated liver enzymes. She had Type I DM for 8 years. When she visited our hospital one month ago, her liver function test had showed abnormal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as 169 U/L (normal value <35) and 172 U/L (normal value <35), respectively. Four weeks later, at the time of the referral, her AST and ALT were elevated strikingly as 1028 U/L and 365 U/L. Other laboratory findings were total bilirubin (TB) 0.5 mg/dL (normal value <1.3), Alkaline phosphatase (ALP) 346 U/L (normal value <85), γ-glutamyl transpeptidase (γ-GT) 321 U/L (normal value <40), hemoglobin A1c (HbA1c) 13.8% (normal value <6), triglyceride (TG) 160 mg/dL, high-density lipoprotein (HDL) 114 mg/dL, creatine kinase (CK) 127 UL (normal value <220). Auto-antibody including anti-nuclear antibody (ANA), smooth muscle antibodies (ASMA) and mitochondrial antibodies (AMA) were all negative. Thyroid function test and serum ceruloplasmin were also normal. The serologic findings for viral infection such as IgM anti-HAV, HBsAg, anti-HCV, HCV-RNA, cytomegalovirus and Epstein–Barr virus were also all negative. Her height, weight, body mass index (BMI) and waist circumference were 165.1 cm, 50.8 kg, 18.6 kg/m² and 72 cm respectively. Abdominal Ultrasonography (US) showed just a mild fatty change of
liver and mild hepatomegaly (Fig. 1). She was not an alcohol or drug consumer and was not taking any medication except insulin. In addition, she did not show any symptom and sign compatible with acute hepatitis. So, we recommend her for a liver biopsy to elucidate the cause of acute elevation of liver enzyme. In hematoxylin and eosin (H&E) stain, liver biopsy showed normal liver architecture with no evidence of hepatocellular injury, inflammation, fibrosis, or steatosis. However, the hepatocytes were diffusely swollen with pale cytoplasm. The periodic acid-Schiff (PAS) staining showed abundant glycogen accumulation within hepatocytes. So, histologically, it was diagnosed as a glycogenic hepatopathy (Fig. 2). Eight weeks later, her transaminases were dropped suddenly without any special management. After this event, although we tried to control her sugar level strictly, her sugar control was still poor and HbA1c was maintained above 11% with mild fluctuation. Until now, her liver enzymes also have shown severe fluctuation continuously as like relapsing hepatitis (Fig. 3A).

Case 2

A 26-year old female was referred to a hepatologist for evaluation of elevated liver enzymes. She had been Type I DM for 9 years. Her glycemia had been poorly controlled with several episodes of DKA & DM gastropathy. When she visited our hospital 4 weeks ago, her AST and ALT had shown relatively mild elevation as 218 and 213 U/L, respectively. At the time of the referral, her AST and ALT were elevated strikingly to 914 U/L and 307 U/L. Other laboratory findings were TB 0.5 mg/dL, ALP 189 U/L, γ-GT 294 U/L, HbA1c 12.9%, TG 185 mg/dL, HDL 112 mg/dL CK 112 U/L. ANA, ASMA and AMA were all negative. Thyroid function test and serum ceruloplasmin were also normal. The serologic findings for viral infection were also all negative. Her height, weight, body mass index (BMI) and waist circumference were 154.3 cm, 56.3 kg, 23.6 kg/m² and 79 cm, respectively. Abdominal US showed just a mild fatty change of liver. She had no history of taking alcohol or drug except insulin. In addition, she did not show any symptom and sign compatible with acute hepatitis. In liver biopsy, histological findings were compatible with GH. Four weeks later, her transaminases dropped spontaneously without any special management. After this event, her glycemic control has been still poor and HbA1c has been maintained above 13%, liver enzyme levels have shown continuous fluctuation (Fig. 3B).

Case 3

A 20-year old female with type I DM during 10 years was referred to a hepatologist for elevated liver enzymes. When she visited our hospital 8 weeks ago, her AST and ALT levels were within normal range as 13 and 9 U/L, respectively. At the time of the referral, her AST and ALT were elevated strikingly to 1,310 U/L and 346 U/L. Other laboratory finding such as TB (0.2 mg/dL), ALP (132 U/L), γ-GT (15 U/L), TG (112 mg/dL), HDL (36 mg/dL), CK 86
UL, thyroid function test, serum ceruloplasmin level were all normal. ANA, ASMA and AMA were also negative. The serologic findings for viral infection were also all negative. There was no history of taking alcohol or drug except insulin. Her glycemic control had been poor and HbA1c was 13.6%. Her height, weight, body mass index (BMI) and waist circumference were 149.8 cm, 47.1 kg and 21 kg/m², respectively. Abdominal US showed just a mild fatty change of liver. As former two cases, she did not show any symptom and sign compatible with acute hepatitis and GH was confirmed by liver biopsy. During the follow up, her glycemic control has been still poor and HbA1c has been maintained above 15%. However, her liver enzyme levels have shown dramatically down and maintenance within normal range (Fig. 3C).

**DISCUSSION**

We reported three cases of GH which were associated with type I diabetes mellitus, causing a clinical picture of acute and relapsing hepatitis. GH can cause severe, but reversible elevations of serum transaminase levels in patients with poorly controlled type I diabetes due to hepatic glycogen accumulation. Long-standing hyperglycemia, over insulin use, glucose given to control hypoglycemia and increased concentrations of the counter regulatory hormones have been known as risk factors for hepatic glycogen accumulation in patients with type I DM by their actions on the glycogen phosphorylase and synthase enzymes.6-8

The typical clinical findings of GH are hepatomegaly and elevated liver enzymes, especially transaminases.2,3,9-14 However, there is no histological evidence that suggests the enzyme elevations are due to liver necrosis, so their elevation is considered as a result of hepatocyte’s membrane injury to cause enzyme “leakage” instead of cell death. However, the exact mechanism as well as prevalence has not been well known. Liver biopsy is helpful to confirm the diagnosis of GH. Histological features in GH are characterized by large, swollen, glycogen-laden hepatocytes and glycogenated nuclei without significant fatty change, inflammation, lobular spotty necrosis or fibrosis.1

The abnormality of transaminase in GH has been known to be easily treatable by improvement of glycemic control in a short time within 2 to 14 weeks.5,12,15 However, as seen in our case, the changes of liver enzyme levels showed somewhat different pattern compared with previous reported cases. The sudden elevation and dropping of transaminase did not showed any definitive correlation with the glycemic control (the change of HbA1C) and continuous fluctuation of transaminase as like relapsing hepatitis in case 1 and 2 is also unusual pattern compared to previous reports. In addition, there was no insulin dose-up even in acute flare-up phase of transaminase. So, it suggests that the changes of transaminases can be related with not only poor glycemic control or insulin therapy but also another factor which has not been clarified. In addition, in all cases, the AST dominant elevation compared to ALT is also impressive finding. Therefore, to elucidate the risk factors and more complete pathophysiology, more advanced systemic review and research have to be performed.

Clinically, to distinguish GH from NAFLD is important, because as mentioned above, the prognosis of both diseases are different. GH has been known to have benign nature whereas NAFLD could progress into advance liver disease such as cirrhosis or hepatocellular carcinoma.2,3 Including our cases, overall GH in diabetic patients with hepatomegaly and abnormal liver enzymes within 5-10 times of upper normal range have often been assumed to have NAFLD rather than GH in the initial diagnostic process. GH is a rare condition and many clinicians are unaware of it if no biopsy is obtained.15 As mentioned above, especially in case of mild transaminases elevation in diabetic patients, liver biopsy is essential in differential diagnosis of GH with NAFLD. In addition, US finding is not helpful in distinguishing NAFLD from GH because both fatty liver and glycogen overload could show similar US finding as mild hyperechoic hepatic parenchyma.3,6,10,11 Consequently, the condition is often misdiagnosed and it result in wasting medical resources.

**CONCLUSION**

We encountered three cases of GH within only one year. It may suggest that many cases of GH have been missed due to a lack of interest by clinician. Clinician’s awareness of GH should prevent diagnostic delay and misdiagnosis and will provide better insight and management for the GH.

**Conflicts of Interest**

The authors have no conflicts to disclose.

**REFERENCES**

1. Mauriac P. Gros ventre, hepatomegalie, troubles de la croissance chez les enfants diabetiques traits depuis plusieurs annes par
1. l’insuline. Gax Hebdo Med Bordeaux 1930;26:402-410.
2. Torbenson M, Chen YY, Brunt E, Cummings OW, Gottfried M, Jakate S, et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006;30:508-513.
3. Chatila R, West AB. Hepatomegaly and abnormal liver tests due to glycogenesis in adults with diabetes. Medicine (Baltimore) 1996;75:327-333.
4. Park J, Song DH, Park JS, Nam JY, Kim CS, Kim DM, et al. A case of hepatomegaly due to diabetic glycogenesis reversed by glycemic control. J Korean Soc Endocrinol 2004;19:223-228.
5. Lee SH, Kwon HS, Shin JA, Kim WC, Kim JH, Choi YH, et al. A case of hepatic glycogenesis in a patient with uncontrolled type 1 diabetes mellitus. J Korean Diabetes Assoc 2006;30:82-86.
6. Munns CF, McCrossin RB, Thomsett MJ, Batch J. Hepatic glycogenesis: reversible hepatomegaly in type 1 diabetes. J Paediatr Child Health 2000;36:449-452.
7. Tsujimoto T, Takano M, Nishiofuku M, Yoshiji H, Matsumura Y, Kuriyama S, et al. Rapid onset of glycogen storage hepatomegaly in a type-2 diabetic patient after a massive dose of long-acting insulin and large doses of glucose. Intern Med 2006;45:469-473.
8. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 1998;101:1203-1209.
9. Nakamura M, Ohashi M, Goto K, Tanabe Y, Hiroshige K, Nawata H. Diabetes mellitus-associated glycogen storage hepatomegaly: report of a case and review of the Japanese literature. Fukuoka Igaku Zasshi 1993;84:354-358.
10. Carcione L, Lombardo F, Messina MF, Rosano M, De Luca F. Liver glycogenesis as early manifestation in type 1 diabetes mellitus. Diabetes Nutr Metab 2003;16:182-184.
11. Torres M, Lopez D. Liver glycogen storage associated with uncontrolled type 1 diabetes mellitus. J Hepatol 2001;35:538.
12. Hudacko RM, Manoukian AV, Schneider SH, Fyle B. Clinical resolution of glycogenic hepatopathy following improved glycemic control. J Diabetes Complications 2008;22:329-330.
13. Bassett JT, Veerappan GR, Lee DH. Glycogenic hepatopathy: a rare cause of increased aminotransferase levels in a diabetic patient. Clin Gastroenterol Hepatol 2008;6:A26.
14. Abaci A, Bekem O, Unuvar T, Ozer E, Bober E, Arslan N, et al. Hepatic glycogenesis: a rare cause of hepatomegaly in Type 1 diabetes mellitus. J Diabetes Complications 2008;22:325-328.
15. Fridell JA, Saxena R, Chalasani NP, Goggins WC, Powelson JA, Cummings OW. Complete reversal of glycogen hepatopathy with pancreas transplantation: two cases. Transplantation 2007;83:84-86.
16. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002;9:37-51.